Mostrar el registro sencillo del ítem
A randomised controlled trial to evaluate a medication monitoring system for TB treatment
dc.contributor.author | Acosta, J. | |
dc.contributor.author | Flores, P. | |
dc.contributor.author | Alarcón, M. | |
dc.contributor.author | Grande-Ortiz, M. | |
dc.contributor.author | Moreno-Exebio, L. | |
dc.contributor.author | Puyen, Z. M. | |
dc.date.accessioned | 2022-03-04T11:11:49Z | |
dc.date.available | 2022-03-04T11:11:49Z | |
dc.date.issued | 2022-01-01 | |
dc.identifier.issn | 10273719 | |
dc.identifier.doi | 10.5588/ijtld.21.0373 | |
dc.identifier.uri | http://hdl.handle.net/10757/659237 | |
dc.description.abstract | BACKGROUND: Adherence to TB treatment and therefore treatment success could be improved using digital adherence technology. OBJECTIVE: To evaluate the effectiveness of a medication event reminder monitor system (MERM) on treatment success and treatment adherence in patients with drug-susceptible pulmonary TB in Perú. METHODS: This was an experimental, randomised, open-label, controlled study conducted among patients in the second phase of TB treatment. The intervention group received their medications through MERM with the support of a treatment monitor, whereas the control group used the usual strategy. Participants were followed until they completed the 54 doses of the second phase of treatment. RESULTS: The study included 53 patients in each group; four in the intervention group withdrew from the study. Treatment success was significantly more frequent in the MERM group (RR 1.15, 95% CI 1.02–1.30; P = 0.0322). There was no significant difference in the adherence outcomes; however, the percentage of patients who missed at least one dose and patients with more than 10% of total doses missed were lower in the intervention group. CONCLUSION: The use of MERM in the second phase of treatment showed a significant improvement in the treatment success rate in patients with drug-susceptible pulmonary TB. | es_PE |
dc.description.sponsorship | National Institutes of Health | es_PE |
dc.format | application/pdf | es_PE |
dc.language.iso | eng | es_PE |
dc.publisher | International Union Against Tuberculosis and Lung Disease | es_PE |
dc.relation.url | https://www.ingentaconnect.com/content/iuatld/ijtld/2022/00000026/00000001/art00009 | es_PE |
dc.rights | info:eu-repo/semantics/openAccess | es_PE |
dc.rights | Attribution-NonCommercial-ShareAlike 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.source | Universidad Peruana de Ciencias Aplicadas (UPC) | es_PE |
dc.source | Repositorio Academico - UPC | es_PE |
dc.subject | Digital adherence technologies | es_PE |
dc.subject | Dispenser pillbox | es_PE |
dc.subject | Treatment adherence | es_PE |
dc.subject | Treatment success | es_PE |
dc.title | A randomised controlled trial to evaluate a medication monitoring system for TB treatment | es_PE |
dc.type | info:eu-repo/semantics/article | es_PE |
dc.identifier.eissn | 18157920 | |
dc.identifier.journal | International Journal of Tuberculosis and Lung Disease | es_PE |
dc.description.peerreview | Revisión por pares | es_PE |
dc.identifier.eid | 2-s2.0-85123036570 | |
dc.identifier.scopusid | SCOPUS_ID:85123036570 | |
dc.source.journaltitle | International Journal of Tuberculosis and Lung Disease | |
dc.source.volume | 26 | |
dc.source.issue | 1 | |
dc.source.beginpage | 44 | |
dc.source.endpage | 49 | |
refterms.dateFOA | 2022-03-04T11:11:50Z | |
dc.identifier.isni | 0000 0001 2196 144X |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Medicina [970]